Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics, Inc. (NASDAQ: PTCT) is a global biopharmaceutical company focused on clinically differentiated medicines for children and adults living with rare disorders. The PTCT news feed on Stock Titan aggregates company announcements, financial updates and regulatory milestones that PTC discloses through press releases and SEC filings.
Investors following PTCT news can see updates on the commercial performance and global rollout of products such as Sephience (sepiapterin) for phenylketonuria (PKU), as well as revenue contributions from the company’s Duchenne muscular dystrophy franchise, which includes Translarna (ataluren) and Emflaza (deflazacort). News items also cover royalty revenue from Evrysdi (risdiplam) and changes in royalty arrangements, such as the sale of certain Evrysdi royalty rights to Royalty Pharma.
PTC Therapeutics regularly reports quarterly and annual financial results, including total revenue, product revenue, royalty and collaboration revenue, and details on GAAP and non-GAAP R&D and SG&A expenses. Corporate updates often highlight pipeline and regulatory developments, including FDA meetings for programs like votoplam in Huntington’s disease and vatiquinone in Friedreich’s ataxia, as well as ongoing review of the Translarna NDA.
The company also issues news about regulatory approvals and launches in different regions, such as Sephience approvals in the EU, US and Japan, and about R&D-focused events and investor conference presentations. In addition, PTC discloses equity inducement grants under Nasdaq Listing Rule 5635(c)(4), illustrating its use of stock options and restricted stock units as part of employee compensation.
By monitoring the PTCT news page, readers can track how product launches, regulatory decisions, collaborations, royalty transactions and capital markets activities shape the company’s progress in the rare disease biopharmaceutical sector.
PTC Therapeutics hosted a conference call on February 4, 2021, at 5:30 p.m. E.T. to discuss results from its clinical study 045 of Translarna™ (ataluren) for treating patients with nonsense mutation Duchenne muscular dystrophy. The call featured access via phone and a live webcast, both providing crucial insights into this rare genetic disorder. Duchenne muscular dystrophy leads to muscle weakness and fatal complications, primarily affecting males. Translarna focuses on restoring protein production in affected patients, currently licensed in the European Economic Area.
PTC Therapeutics (NASDAQ: PTCT) has launched the seventh annual STRIVE Awards program aimed at supporting Duchenne muscular dystrophy patient advocacy organizations. This year, a new category has been added to facilitate the transition of Duchenne patients from adolescence to adulthood. The awards emphasize the increasing life expectancy of Duchenne patients, now reaching their 30s and 40s, which highlights the need for enhanced quality of life support. The submission deadline is March 15, with winners announced in September 2021.
On January 6, 2021, PTC Therapeutics (NASDAQ: PTCT) approved inducement grants for 10 new employees, comprising 13,465 stock options and 4,665 restricted stock units (RSUs). These grants are part of the employee's compensation and comply with NASDAQ Listing Rule 5635(c)(4). The options have an exercise price of $66.49 and a 10-year term, vesting over four years. RSUs will also vest over four years with annual anniversaries. This initiative reflects PTC's commitment to attracting talent in the biopharmaceutical sector.
PTC Therapeutics (NASDAQ: PTCT) presented its R&D pipeline updates and commercial progress at the J.P. Morgan Healthcare Conference on January 11, 2021. Highlights from 2020 include a DMD franchise revenue of approximately $331 million, with significant contributions from Translarna and Emflaza. The company anticipates 2021 revenues between $355 and $375 million for the DMD franchise and plans to conduct several clinical trials. Preliminary financial results indicate approximately $1.1 billion in cash and equivalents by year-end 2020.
PTC Therapeutics announced its participation in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 7:30 a.m. EST. The event will be webcast live, with a replay available for 30 days. The company focuses on developing and commercializing innovative medicines for rare disorders, aiming to improve patient access to necessary treatments. Interested parties are encouraged to join the webcast via the investor relations section on PTC's website.
PTC Therapeutics (NASDAQ: PTCT) announced the approval of non-statutory stock options for 12,500 shares and 4,360 restricted stock units (RSUs) to 10 new employees as part of their employment compensation. These awards were granted under NASDAQ's inducement grant exception on December 15, 2020. The stock options have an exercise price of $66.37 and will vest over four years. The RSUs will follow a similar vesting schedule. PTC, focused on rare disorders, continues to strengthen its workforce to support its mission in biopharmaceutical development.
PTC Therapeutics will host a webinar on December 15, 2020, at 12:00 noon ET, focusing on Translarna, a treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD). The session will discuss clinical and real-world data, commercial success, and potential regulatory milestones in the United States. Results from Study PTC124-GD-045-DMD are expected in Q1 2021. The webinar can be accessed via phone or through the company's website, with a replay available for 30 days.
PTC Therapeutics (NASDAQ: PTCT) announced on December 2, 2020, the approval of stock options and restricted stock units (RSUs) for 47 new employees as part of their compensation package. The grant includes 41,955 stock options at an exercise price of $63.86 and 20,735 RSUs, both vesting over four years. These inducement grants comply with NASDAQ Listing Rule 5635(c)(4) and were approved by the Compensation Committee to attract new talent.
PTC Therapeutics announced that Translarna (ataluren) has received marketing approval in the Russian Federation for treating nonsense mutation Duchenne muscular dystrophy (nmDMD), impacting an estimated 13% of DMD patients. This approval is significant as Translarna is the only medicine targeted at the underlying cause of nmDMD in approved regions. CEO Stuart W. Peltz highlighted the demand from Russian physicians and the identification of nmDMD patients who may benefit. This marks an important milestone in PTC's goal to globally provide access to this treatment.
PTC Therapeutics (NASDAQ: PTCT) has initiated the registration-directed Phase 3 MOVE-FA study for vatiquinone (PTC743) in children and young adults with Friedreich ataxia (FA), a rare neurodegenerative disorder. This pivotal trial comes after vatiquinone showed positive results in a Phase 2 trial, impacting disease severity over 24 months. The trial will enroll approximately 110 participants across multiple regions, with primary endpoints focused on the modified Friedreich ataxia rating scale. The FDA has granted vatiquinone both Orphan Drug and Fast Track Designations.
FAQ
What is the current stock price of Ptc Therapeutics (PTCT)?
What is the market cap of Ptc Therapeutics (PTCT)?
